Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 194

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 194
---
2025, the 2025 Loan Agreements have been extended until November 30, 2025.

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

All
of our executive officers have employment or consultancy agreements with us which contain
customary provisions and representations, including confidentiality, non-competition, non-solicitation
and inventions assignment undertakings by the executive officers. None of our employment
or service provider agreements contain any terms providing for severance benefits. Under
current applicable Israeli employment laws, we may not be able to enforce (either in whole
or in part) covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. See “Management—Compensation
of Executive Officers and Directors”. In addition, certain of our other executive officers
have service provider agreements with us pursuant to which they are engaged by us as independent
contractors. These service provider agreements prohibit such executive officers from engaging
in activities that would present a conflict of interest to us or would involve providing
services to our competitors. See “Management— Engagement Agreements with Executive
Officers” for additional information.

Investors’ Rights Agreement

On February 5, 2016, we entered into an investors’ rights agreement, or the IRA, with several of our shareholders, who hold in the aggregate a total of 2,365,980 Ordinary Shares. Pursuant to the IRA, the shareholders have a right to require that we register such 2,365,980 Ordinary Shares under the Securities Act under specific circumstances and will have incidental registration rights as described below. On March 20, 2025, our shareholders approved the termination of the IRA subject to the completion of this offering. Accordingly, the IRA will be of no further effect thereafter.

<div align='center'>117

DESCRIPTION OF SHARE CAPITAL</div>

The following description
of our share capital and provisions of our amended and restated articles of association which will be effective upon the completion of
this offering are summaries and do not purport to be complete. By becoming a shareholder in our Company, you will be deemed to have notice
of and consented to these provisions of our articles of association as amended and restated.

Authorized Capital

Upon the closing of this
offering, our authorized share capital will consist of 22,500,000 Ordinary Shares, no par value per share, of which Ordinary Shares will
be issued and outstanding (assuming that the